Last reviewed · How we verify
[13C]-labeled BI 1584862 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[13C]-labeled BI 1584862 ([13C]-labeled BI 1584862) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [13C]-labeled BI 1584862 TARGET | [13C]-labeled BI 1584862 | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [13C]-labeled BI 1584862 CI watch — RSS
- [13C]-labeled BI 1584862 CI watch — Atom
- [13C]-labeled BI 1584862 CI watch — JSON
- [13C]-labeled BI 1584862 alone — RSS
Cite this brief
Drug Landscape (2026). [13C]-labeled BI 1584862 — Competitive Intelligence Brief. https://druglandscape.com/ci/13c-labeled-bi-1584862. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab